Analyses of nanoformulated antiretroviral drug charge, size, shape and content for uptake, drug release and antiviral activities in human monocyte-derived macrophages.
about
Target shape dependence in a simple model of receptor-mediated endocytosis and phagocytosisCell delivery of therapeutic nanoparticlesDrug synergy of tenofovir and nanoparticle-based antiretrovirals for HIV prophylaxisCellular Responses and Tissue Depots for Nanoformulated Antiretroviral TherapyA review of nanotechnological approaches for the prophylaxis of HIV/AIDS.Long-acting nanoformulated antiretroviral therapy elicits potent antiretroviral and neuroprotective responses in HIV-1-infected humanized mice.Endosomal trafficking of nanoformulated antiretroviral therapy facilitates drug particle carriage and HIV clearance.Pharmacodynamics of long-acting folic acid-receptor targeted ritonavir-boosted atazanavir nanoformulations.Opposing regulation of endolysosomal pathways by long-acting nanoformulated antiretroviral therapy and HIV-1 in human macrophagesProlonged-acting, multi-targeting gallium nanoparticles potently inhibit growth of both HIV and mycobacteria in co-infected human macrophages.The clinical role and cost-effectiveness of long-acting antiretroviral therapyComparative manufacture and cell-based delivery of antiretroviral nanoformulations.Rodent models for HIV-associated neurocognitive disorders.Mononuclear phagocyte intercellular crosstalk facilitates transmission of cell-targeted nanoformulated antiretroviral drugs to human brain endothelial cells.Nanoparticle based galectin-1 gene silencing, implications in methamphetamine regulation of HIV-1 infection in monocyte derived macrophagesPharmacodynamic and antiretroviral activities of combination nanoformulated antiretrovirals in HIV-1-infected human peripheral blood lymphocyte-reconstituted mice.Functional proteome of macrophage carried nanoformulated antiretroviral therapy demonstrates enhanced particle carrying capacityPreclinical pharmacokinetics and tissue distribution of long-acting nanoformulated antiretroviral therapyNovel intravaginal nanomedicine for the targeted delivery of saquinavir to CD4+ immune cells.Macrophage folate receptor-targeted antiretroviral therapy facilitates drug entry, retention, antiretroviral activities and biodistribution for reduction of human immunodeficiency virus infectionsCreation of a Long-Acting Nanoformulated 2',3'-Dideoxy-3'-ThiacytidineNanoparticle-based drug delivery to improve the efficacy of antiretroviral therapy in the central nervous systemMacrophages associated with tumors as potential targets and therapeutic intermediates.Nanoformulation strategies for the enhanced oral bioavailability of antiretroviral therapeutics.Polycaprolactone/maltodextrin nanocarrier for intracellular drug delivery: formulation, uptake mechanism, internalization kinetics, and subcellular localizationA recent trend of drug-nanoparticles in suspension for the application in drug delivery.Nanomedicine formulations for the delivery of antiviral drugs: a promising solution for the treatment of viral infections.Encapsulation of ritonavir in solid lipid nanoparticles: in-vitro anti-HIV-1 activity using lentiviral particles.Development and characterization of a long-acting nanoformulated abacavir prodrugIntracellular disposition of chitosan nanoparticles in macrophages: intracellular uptake, exocytosis, and intercellular transport.Dual drug delivery system for targeting H. pylori in the stomach: preparation and in vitro characterization of amoxicillin-loaded Carbopol® nanospheresSmall magnetite antiretroviral therapeutic nanoparticle probes for MRI of drug biodistribution.Pharmaceutical suspension containing both immediate/sustained-release amoxicillin-loaded gelatin nanoparticles: preparation and in vitro characterization.UPLC-MS/MS quantification of nanoformulated ritonavir, indinavir, atazanavir, and efavirenz in mouse serum and tissuesNanomedicines for HIV therapy.Complex encounters: nanoparticles in whole blood and their uptake into different types of white blood cells.Antiretroviral solid drug nanoparticles with enhanced oral bioavailability: production, characterization, and in vitro-in vivo correlation.Creation of a nanoformulated cabotegravir prodrug with improved antiretroviral profiles.Intranasal administration of antiretroviral-loaded micelles for anatomical targeting to the brain in HIV.Interview: Nanomedicine and the fight against HIV/AIDS.
P2860
Q27316966-D81287DF-2C81-4E5C-AB7C-A5F7A73D79E2Q28385606-B839776C-538F-4266-8ACB-35206B11E354Q28486428-B377D919-126D-4C2F-ADD4-3D1B1F21C1A8Q28551873-D4ADEB36-5CDC-4F14-841B-45888FD392FFQ30431343-9717228E-C5C3-447F-A2EA-5DB93941277CQ33625213-5D6FDE37-2790-49D3-826E-75632B384D5EQ34059457-88E98B8A-64ED-49B4-9705-3766A5CF868AQ34745586-E88A5F51-9348-4B27-947B-64E2ED3AEDB0Q35016131-A3D46F33-3D84-469D-BDF7-64CCFD3562CDQ35153311-34D4288D-AE79-419E-8D31-1270A30560C0Q35197271-A8A33A41-C6EB-4118-9CE3-0B1FA8DE5FD8Q35677168-0BE5FC90-0E05-49A1-822D-83569B078318Q35803957-A5092518-DB72-4A8B-BCB9-D3957564BEC6Q35979166-C9C60CAD-8B15-4969-BEAB-445BF5860E7DQ36166289-88C2CB22-E70B-4459-8E8A-F517C9F359DEQ36603756-6C814D14-5104-412C-97BA-E90BAD8C890BQ36875347-FD6967FC-1154-44F3-8714-9ABEA310B264Q36969787-2AE8AD17-16EF-4A6F-B706-7F9B401CE216Q37095750-E54112B5-B249-4FE0-8ED9-AE9DD271F126Q37188867-C6AB6B4F-05C5-421B-B69D-70FC27415F0CQ37639081-47CBDD4E-59F2-426C-96E0-89A2EEA6ADC9Q37698620-4893ABDC-3B20-4DB9-BB0B-490066715E2DQ38211726-EDDDD356-81D5-4D7C-BB39-C3DBF39EDED0Q38495022-3C714458-DED8-4112-8C15-D63CE8D20E89Q38845608-E8B88E78-0876-4D70-94F1-B3AB2C619D0AQ38985268-9D6D31AF-3780-4022-89EF-D5AE956DD9B7Q40105941-7DB5DFDE-493A-4B40-9C1C-DB42705DEDCEQ40215796-7B3BF681-6B0B-4C34-BF69-E2E4DBAB7BAAQ41280373-D1CAA772-434C-4FDA-BE7A-9B9BDDCA58DFQ41634406-1A8A9F23-375E-46C5-B83A-D940024CAE92Q41762743-33049128-0040-459F-9FDE-EFF31F424363Q41905223-34F5D20B-ED42-4E2D-A025-4ADCA13F8C3BQ42125818-E2F5F486-64EE-4490-9495-3ADBFBC0CDCCQ42844098-22EDC3C0-BF30-472E-B1A2-4A81AB907B6EQ44880910-4153B3F0-4F6A-42F5-8CFE-7CCBC6C3FD24Q46308403-6F13FCB7-D5C1-48F9-9AE9-B6CDB57CF71BQ46448056-F31BC6AF-E562-440E-8EA8-EF8CBD037F8DQ47603651-1EA59382-5CA3-488C-A9EB-1666FA6C43A9Q48284053-A2D893C9-64A4-4662-8EC1-B21E185B7E6CQ48375952-02E69918-1971-4E3F-92A7-2DBEC419829F
P2860
Analyses of nanoformulated antiretroviral drug charge, size, shape and content for uptake, drug release and antiviral activities in human monocyte-derived macrophages.
description
2010 nî lūn-bûn
@nan
2010 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Analyses of nanoformulated ant ...... monocyte-derived macrophages.
@ast
Analyses of nanoformulated ant ...... monocyte-derived macrophages.
@en
Analyses of nanoformulated ant ...... monocyte-derived macrophages.
@nl
type
label
Analyses of nanoformulated ant ...... monocyte-derived macrophages.
@ast
Analyses of nanoformulated ant ...... monocyte-derived macrophages.
@en
Analyses of nanoformulated ant ...... monocyte-derived macrophages.
@nl
prefLabel
Analyses of nanoformulated ant ...... monocyte-derived macrophages.
@ast
Analyses of nanoformulated ant ...... monocyte-derived macrophages.
@en
Analyses of nanoformulated ant ...... monocyte-derived macrophages.
@nl
P2093
P2860
P1476
Analyses of nanoformulated ant ...... n monocyte-derived macrophages
@en
P2093
Andrea Martinez-Skinner
Ari S Nowacek
Georgette Kanmogne
Howard E Gendelman
JoEllyn McMillan
R Lee Mosley
Shantanu Balkundi
Tatiana Bronich
P2860
P304
P356
10.1016/J.JCONREL.2010.11.019
P407
P577
2010-11-23T00:00:00Z